- Home
- ACRE vs MXCT Comparison
ACRE vs MXCT Comparison
Compare ACRE & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRE
- MXCT
- Stock Information
- Founded
- ACRE 2011
- MXCT 1999
- Country
- ACRE United States
- MXCT United States
- Employees
- ACRE N/A
- MXCT N/A
- Industry
- ACRE Real Estate Investment Trusts
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ACRE Real Estate
- MXCT Health Care
- Exchange
- ACRE Nasdaq
- MXCT Nasdaq
- Market Cap
- ACRE 270.6M
- MXCT 239.2M
- IPO Year
- ACRE 2012
- MXCT 2021
- Fundamental
- Price
- ACRE $4.81
- MXCT $2.06
- Analyst Decision
- ACRE Hold
- MXCT Strong Buy
- Analyst Count
- ACRE 7
- MXCT 1
- Target Price
- ACRE $5.50
- MXCT $9.00
- AVG Volume (30 Days)
- ACRE 458.9K
- MXCT 922.0K
- Earning Date
- ACRE 08-05-2025
- MXCT 08-05-2025
- Dividend Yield
- ACRE 12.37%
- MXCT N/A
- EPS Growth
- ACRE N/A
- MXCT N/A
- EPS
- ACRE N/A
- MXCT N/A
- Revenue
- ACRE $67,129,000.00
- MXCT $37,675,000.00
- Revenue This Year
- ACRE N/A
- MXCT $8.82
- Revenue Next Year
- ACRE N/A
- MXCT $21.12
- P/E Ratio
- ACRE N/A
- MXCT N/A
- Revenue Growth
- ACRE 83.51
- MXCT N/A
- 52 Week Low
- ACRE $3.35
- MXCT $2.03
- 52 Week High
- ACRE $7.99
- MXCT $5.20
- Technical
- Relative Strength Index (RSI)
- ACRE 55.85
- MXCT 39.29
- Support Level
- ACRE $4.76
- MXCT $2.19
- Resistance Level
- ACRE $4.94
- MXCT $2.28
- Average True Range (ATR)
- ACRE 0.12
- MXCT 0.12
- MACD
- ACRE -0.01
- MXCT 0.00
- Stochastic Oscillator
- ACRE 56.90
- MXCT 7.81
About ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.